Comparative Pharmacology
Head-to-head clinical analysis: BOSULIF versus CABOZANTINIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSULIF versus CABOZANTINIB.
BOSULIF vs CABOZANTINIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bosutinib is a tyrosine kinase inhibitor that targets BCR-ABL kinase, as well as SRC family kinases. It inhibits the phosphorylation of tyrosine residues in proteins involved in the BCR-ABL signaling pathway, thereby inhibiting cell proliferation and inducing apoptosis in Philadelphia chromosome-positive (Ph+) leukemia cells.
Small molecule tyrosine kinase inhibitor that targets MET, VEGFR2, RET, AXL, KIT, TIE2, FLT3, and TRKB. Inhibits tumor growth, angiogenesis, and metastasis.
400 mg orally once daily with food.
60 mg orally once daily, taken without food (at least 1 hour before or 2 hours after eating).
None Documented
None Documented
The terminal elimination half-life is approximately 22.5 hours (range 15-34 hours) following a 500 mg oral dose. This supports once-daily dosing, with steady-state achieved within 15 days.
Clinical Note
moderateCabozantinib + Digoxin
"Cabozantinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCabozantinib + Digitoxin
"Cabozantinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCabozantinib + Deslanoside
"Cabozantinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCabozantinib + Acetyldigitoxin
"Cabozantinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 99 hours (range 68–136 hours) in patients with advanced solid tumors, supporting once-daily dosing.
Primarily fecal (approximately 85% of the administered dose), with renal excretion accounting for less than 1% as unchanged drug and 3% as metabolites. Biliary excretion is a significant route for elimination of unchanged drug and metabolites.
Primarily fecal (approximately 54% of administered dose as unchanged drug and metabolites), with renal excretion accounting for approximately 27% (largely as metabolites). Mean total recovery in feces and urine is about 81%.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor